Bone Biologics Corp 8-K

What Happened
Bone Biologics Corporation (BBLG) announced it priced and closed a private placement that raised approximately $2.7 million in net proceeds on July 9, 2026. The company sold 2,112,677 pre‑funded warrants (each exercisable for one share at $0.001) together with Series F and Series G warrants to purchase 2,112,677 shares each, at a combined purchase price of $1.419 per pre‑funded warrant plus accompanying warrants. The offering was conducted under a Securities Purchase Agreement and accompanied by a Registration Rights Agreement; H.C. Wainwright & Co., LLC served as exclusive placement agent.

Key Details

• Securities sold: 2,112,677 Pre‑Funded Warrants; Series F Warrants for 2,112,677 shares; Series G Warrants for 2,112,677 shares.
• Pricing & proceeds: combined purchase price $1.419 per unit; net proceeds to company ≈ $2.7 million after fees. Potential additional gross proceeds if all warrants are exercised on a cash basis ≈ $6.0 million.
• Exercise terms: Series F & G exercise price $1.42 per share; Series F exercisable after shareholder approval and expires 5 years after the later of shareholder approval or resale registration effectiveness; Series G exercisable after shareholder approval and expires 18 months after that later date. Pre‑Funded Warrants exercisable immediately at $0.001 per share. Ownership cap limits exercise to prevent beneficial ownership >4.99% (or 9.99% if elected).
• Placement agent: H.C. Wainwright received a 7.0% cash fee + 1.0% management fee, expense reimbursements (up to $35k) and legal/out‑of‑pocket expenses (up to $50k); placement agent warrants for up to 126,761 shares with $1.775 exercise price were issued.
• Corporate actions & registrations: Company agreed to seek shareholder approval for issuance of the warrants and underlying shares at its next annual meeting or a special meeting within 90 days; agreed to file a resale registration statement within 15 days and use commercially reasonable efforts to have it effective within 45 days (75 days if full SEC review). Offering relied on exemptions under Section 4(a)(2) and Rule 506.

Why It Matters
This financing provides immediate cash (~$2.7M) to fund Bone Biologics’ clinical programs, patent maintenance and working capital while preserving potential future cash inflows (≈$6M) if the warrants are exercised. Investors should note dilution risk if warrants (or placement agent warrants) are exercised and that many warrant features (exercise timing, ownership caps, and resale registration) depend on shareholder approval and the effectiveness of a registration statement. The filing also discloses placement agent fees and customary contractual covenants and restrictions that could affect near‑term financing flexibility.